Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00877032 · ClinicalTrials.gov registry record · Phase 1
Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT00877032 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 57 participants.
The verdict
NCT00877032, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of RN6G in patients with dry, age-related macular degeneration.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL RN6G
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00877032
The ClinicalTrials.gov registry entry for NCT00877032 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00877032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00877032 about?
NCT00877032 is a clinical study titled "Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration". The purpose of this study is to determine the safety and tolerability of RN6G in patients with dry, age-related macular degeneration.
What is the current status of trial NCT00877032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2009-04. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00877032?
The interventions under investigation include: Placebo (BIOLOGICAL), RN6G (BIOLOGICAL).
Who is sponsoring clinical trial NCT00877032?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.